Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of September 21, 2025 [1] Core Insights - The trend of Chinese innovative drugs going global is a significant industry trend, with a notable increase in License-out transactions in the first half of 2025, surpassing the total number for 2024 by over half and increasing transaction amounts by 16% [2] - The report highlights the importance of structural opportunities within the industry, emphasizing the need to select high-quality companies amidst the competitive landscape [2] - The report notes that while the trend of innovative drugs going abroad continues, concerns have arisen due to fewer major transactions and proposed U.S. regulations affecting Chinese drug licensing [2] - The report identifies significant breakthroughs in small nucleic acid drugs, particularly in chronic disease areas such as hypertension, with notable partnerships and potential milestone payments [3] - The report discusses promising clinical data from Chinese ADCs presented at the World Lung Cancer Conference, showcasing competitive advantages in efficacy and safety [4] - The report mentions the advancements in GLP-1 analogs for weight loss, with ongoing developments from both multinational corporations and domestic companies [5] - The CXO sector is expected to gradually recover, driven by an increase in orders and favorable policy changes [6] - The report outlines the completion of expert reviews for the 2025 medical insurance negotiation and commercial insurance innovative drug directories, indicating potential impacts on participating companies [7] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry index has underperformed compared to the CSI 300 index, with a recent weekly decline of 2.07% [22] - Over the past month, the industry has lagged behind the CSI 300 index by 7.79 percentage points [23] 2. Pharmaceutical Sector Trends and Valuation - The current PE (TTM) for the pharmaceutical industry index is 39.77, above the five-year historical average of 31.50 [48] 3. Recent Research Achievements - The report includes various recent research outputs, highlighting the ongoing focus on innovative drug development and market opportunities [50] 4. Recent Industry Policies and News - The report details recent policy updates from the National Medical Insurance Administration regarding drug directory adjustments and the implications for the industry [52][54]

Core Insights - The report indicates a 2.07% week-on-week decline in the Shenwan Pharmaceutical Index, underperforming both the CSI 300 Index and the ChiNext Index during the week of September 15-19, 2025 [1][12] - The focus for the upcoming 1-2 quarters includes significant global conferences related to innovative drugs and the business development (BD) spending rhythm of multinational corporations (MNCs) [1][18] Recent Market Review - The market experienced fluctuations, with a notable rise in coal, electricity, electronics, and real estate sectors, while the pharmaceutical index showed similar volatility, particularly with a larger adjustment on Thursday and Friday [2][13] - The innovative drug sector is currently in a state of adjustment, reflecting a digestion of trading structures and a lack of short-term catalysts [3][14] Future Outlook - The report emphasizes a positive outlook for the pharmaceutical sector in 2025, driven by innovative drugs, with a focus on overseas major pharmaceuticals, small and medium-sized technology revolutions, and the revaluation of generic pharmaceuticals [4][15] - The report suggests that the innovative drug sector is entering a second wave of growth over the next 5-10 years, with the keyword being "disruption" [3][14] Investment Strategy - The report outlines specific investment strategies in the innovative drug sector, highlighting key companies such as Innovent Biologics, BeiGene, and others in various therapeutic areas including oncology and chronic diseases [7][16] - It also identifies emerging technologies such as brain-computer interfaces and AI in medicine as potential investment opportunities [8][16] Upcoming Conferences - Key upcoming global conferences include the ESMO Congress and SABCS, which are expected to influence BD activities and provide insights into the latest advancements in oncology [18][19] Performance Metrics - The report notes that the CSI Innovative Drug Index has increased by 38.55% since the beginning of 2025, outperforming both the Shenwan Pharmaceutical Index and the CSI 300 Index [23][26]

Core Viewpoint - The Chinese innovative drug industry is gradually catching up with Europe and the United States in terms of technology, with some targets and technical pathways already leading globally. The number and value of new drugs authorized for overseas markets continue to increase, leading to world-class pricing and non-linear investment elasticity. The domestic market is experiencing strong growth in demand, with domestic new drug sales continuing to rise, and several innovative pharmaceutical companies have turned losses into profits, entering a stable growth phase [2]. Group 1: Innovative Drugs - The innovative drug sector is witnessing a significant increase in sales driven by strong domestic demand, with a number of innovative companies achieving profitability [2]. - The trend of domestic innovative drugs going overseas is accelerating, with increasing numbers and values of new drug authorizations [2]. - The pricing power of innovative drugs is improving, reflecting the global competitiveness of Chinese pharmaceutical companies [2]. Group 2: High-Value Medical Consumables - The orthopedic sector is expected to see mild price reductions due to continued domestic substitution and accelerated overseas business progress [2]. - The neurosurgery and neurointervention fields are experiencing stable growth post-collection, with new products being launched [2]. - The high-value consumables market is expected to benefit from ongoing domestic replacement and the introduction of new products [2]. Group 3: Medical Devices - The medical device sector is seeing a recovery in bidding prices, with ongoing high-speed growth in bidding data this year [2]. - Companies are entering a phase of inventory reduction, with performance expected to improve in the second half of the year [2]. - The low-value consumables sector is experiencing product upgrades and accelerated expansion into overseas markets [2]. Group 4: Blood Products - The supply side of the blood products industry is concentrating on central state-owned enterprises, gradually clearing the competitive landscape [2]. - The demand side is expected to see continuous upgrades to new products, with industry sentiment gradually improving [2]. Group 5: API (Active Pharmaceutical Ingredients) - The API sector is benefiting from the end of a capital expenditure peak, with three growth logic points driving upward trends: new high-end market products, integrated consolidation and overseas expansion, and cost-leading CDMO [2]. - Leading companies in the API sector are expected to see explosive growth in revenue and profits [2]. Group 6: CXO (Contract Research Organization) - The CXO sector is witnessing a recovery in A+H financing activity, with multiple significant business developments enhancing market confidence [2]. - The focus is on optimizing the supply-side landscape and increasing market share for leading CRO companies [2]. Group 7: Traditional Chinese Medicine and Retail Pharmacy - The traditional Chinese medicine sector is showing signs of recovery, with friendly pricing for new drugs and ongoing observation of collection progress [2]. - The retail pharmacy sector is influenced by the pace of supply-side clearing and business model upgrades, with expectations of increased store closures in the second half of 2025 [2]. Group 8: Research and Development Services - The domestic innovative drug business development is heating up, likely driving downstream demand recovery [2]. - The overseas market presents significant growth opportunities for domestic companies, leveraging cost-effectiveness and service differentiation [2].

Core Viewpoint - The report from CMB International indicates that since September, domestic investors have maintained a stable holding ratio through the Hong Kong Stock Connect, while foreign investors have slightly reduced their holdings in Hong Kong pharmaceutical stocks since mid-year [1] Group 1: Investment Trends - Domestic investors have increased their holdings in leading and innovative pharmaceutical companies, while foreign investors have shown increased interest in cost-effective CXO companies [1] - There has been a general rise in the innovative drug sector, suggesting a gradual accumulation during market corrections [1] Group 2: Recommended Stocks - Specific recommendations include innovative drug companies such as 3SBio and Eucure Biopharma, which have rich short-term catalysts and valuations that do not yet reflect the core value of major products [1] - Other recommended stocks include Sihuan Pharmaceutical, Hutchison China MediTech, and Legend Biotech, which are considered significantly undervalued with clear long-term growth logic [1] - In the CXO sector, companies like WuXi AppTec are highlighted as benefiting from high downstream demand and marginal improvements in financing conditions [1]

Core Viewpoint - The report from CMB International indicates that the Hang Seng Index rose by 1.9% during the week of September 9-16, 2025, while the Hang Seng Healthcare Index fell by 3.0%, ranking 12th among industry indices and underperforming the market [1] Group 1: Market Performance - The Hang Seng Index increased by 1.9% during the specified week [1] - The Hang Seng Healthcare Index decreased by 3.0%, underperforming the overall market [1] Group 2: Investment Trends - Domestic investors maintained a stable holding ratio through the Hong Kong Stock Connect, while foreign investors slightly reduced their holdings in Hong Kong pharmaceuticals since mid-year [1] - Domestic investors increased their positions in leading and innovative pharmaceutical companies, while foreign investors favored cost-effective CXO companies [1] - There was a reduction in positions for innovative drug targets favored by domestic investors [1] Group 3: Regulatory Concerns - Recent statements by Trump regarding increased restrictions on the import of Chinese pharmaceuticals have raised market concerns about the overseas prospects of domestic innovative drugs [1] - The actual impact of these statements is considered limited due to the low participation of multinational corporations (MNCs) and the increasing reliance of MNCs on Chinese pharmaceutical innovation [1] - The report emphasizes the importance of timing and stock selection in the innovative drug sector after a broad market rally, recommending gradual positioning during market corrections [1]

Core Viewpoint - The Chinese innovative drug industry is gradually catching up with Europe and the United States in terms of technology, with some targets and technical pathways already leading globally. The number and value of new drugs authorized for overseas markets continue to increase, leading to world-class pricing and non-linear investment elasticity. The domestic market is experiencing strong growth in demand, with domestic new drug sales continuing to rise, and several innovative pharmaceutical companies have turned losses into profits, entering a stable growth phase [2]. Group 1: Innovative Drugs - The innovative drug sector is witnessing a significant increase in sales driven by strong domestic demand, with a number of innovative companies achieving profitability [2]. - The trend of domestic innovative drugs going overseas is accelerating, with increasing numbers and values of new drug authorizations [2]. - The industry is positioned for a "Davis double" effect, where both performance and valuation are expected to improve [2]. Group 2: High-Value Medical Consumables - The orthopedic sector is expected to see mild price reductions, while domestic replacements continue to grow, and overseas business progresses rapidly [2]. - The neurosurgery and neurointervention fields are stabilizing after centralized procurement, with new products expected to contribute to growth [2]. Group 3: Medical Devices - The medical device sector is experiencing a high-speed growth in bidding data, with companies entering a destocking phase, which is expected to improve performance in the second half of the year [2]. - The low-value consumables sector is seeing continuous product upgrades and accelerated expansion into overseas markets [2]. Group 4: Blood Products - The supply side of the blood products industry is increasingly concentrated among state-owned enterprises, leading to a clearer competitive landscape [2]. - The demand side is expected to upgrade towards new products, gradually improving the industry's overall health [2]. Group 5: API (Active Pharmaceutical Ingredients) - The industry is at an upward turning point due to the end of a capital expenditure peak, combined with three growth drivers: new high-end market products, integrated consolidation and overseas expansion, and cost-leading CDMO [2]. - Leading companies are expected to see explosive growth in revenue and profits in the medium term [2]. Group 6: CXO (Contract Research Organization) - The CXO sector is seeing a revival in A+H financing activity, with multiple significant business developments enhancing market confidence [2]. - The focus is on optimizing the supply-side landscape and increasing market share for leading CRO companies [2]. Group 7: Traditional Chinese Medicine and Retail Pharmacy - The traditional Chinese medicine sector is showing signs of recovery, with friendly pricing for new drugs, while the retail pharmacy sector is influenced by supply-side adjustments and business model upgrades [2]. - The performance of offline pharmacies is expected to improve in the second half of 2025, with leading chains like YaoXingTang making progress in store upgrades [2]. Group 8: Research Reports - A series of in-depth research reports on various companies and sectors within the pharmaceutical and medical device industries have been published, highlighting their growth potential and market positioning [3][4].

Market Overview - The Hang Seng Index slightly declined by 8 points or 0.03%, closing at 438 points on September 16, 2025[1] - The Hang Seng Tech Index rose by 0.6%, closing at 6,077 points[1] - Market turnover was recorded at HKD 294.1 billion, with a net outflow of HKD 3.18 billion from the Hong Kong Stock Connect[1] Economic Indicators - Investor sentiment is cautious, awaiting the outcome of the upcoming FOMC meeting[1] - The U.S. Federal Reserve's potential rate cut is anticipated to have limited impact on Hong Kong stocks due to already high valuations[2] - Sectors sensitive to interest rates, such as AI, robotics, semiconductors, and real estate, may benefit more directly from monetary policy changes[2] Sector Performance - The automotive parts sector saw a significant rise, with Sanhua Intelligent Controls (2050 HK) increasing by 12.8%[3] - The pharmaceutical sector experienced minor declines, with a focus on innovative drugs and leading CXO companies[3] - The renewable energy sector showed mixed performance, with solar stocks generally rising, such as Xinyi Solar (968 HK) up by 2.1%[4] Company Insights - Chaoyun Group (6601 HK) reported a 7.2% increase in revenue to RMB 1.34 billion, with pet category revenue doubling to RMB 96 million, a growth of 101.4%[5][6] - The overall gross margin improved by 2.9 percentage points to 49.3%[5] - The company plans to expand its offline pet store count to 200 by 2027 and is expected to maintain a high dividend payout ratio of 80%[8] Investment Strategy - The report suggests focusing on technology leaders and sectors benefiting from industrial upgrades, such as semiconductors and AI, amidst market volatility[9] - The anticipated rate cut by the Fed is expected to attract foreign capital back to Hong Kong stocks, with a focus on sectors showing strong earnings certainty[9]

Investment Rating - The report maintains a positive outlook on innovative drugs, AI healthcare, and brain-computer interfaces [1]. Core Insights - The report analyzes 362 pharmaceutical listed companies, including those on the Sci-Tech Innovation Board, reporting a total revenue of 1,084.5 billion yuan in H1 2025, a decrease of 2.1% year-on-year. The net profit attributable to shareholders was 103.64 billion yuan, down 1.1%, while the net profit excluding non-recurring items was 88.905 billion yuan, down 9.4% [3][17]. - In H1 2025, 165 companies achieved revenue growth, accounting for 46% of the total, while 165 companies also reported positive net profit growth, also 46% [17]. Summary by Relevant Sections Overall Industry Performance - The pharmaceutical industry faced pressure from policies and macroeconomic conditions, leading to a decline in performance in H1 2025 [19]. - The overall revenue for the industry decreased by 2.1%, with a net profit decline of 1.1% [46]. Subsector Analysis - **Innovative Drugs and Formulations**: Revenue was 194.6 billion yuan (-2.0%), with net profit at 25.8 billion yuan (+1.2%) [5]. - **Medical Devices**: Revenue decreased to 96.8 billion yuan (-5%), with net profit down 16.9% [5]. - **CXO Services**: Revenue increased by 13.8% to 44.85 billion yuan, with net profit rising 64.6% [5]. - **Active Pharmaceutical Ingredients**: Revenue remained stable at 52.88 billion yuan, with net profit increasing by 19.1% [5]. - **Life Sciences**: Revenue was 3.9 billion yuan (-1.8%), with net profit down 3.6% [7]. - **Medical Services**: Revenue grew by 0.9% to 28.3 billion yuan, but net profit fell by 10.2% [7]. - **Blood Products**: Revenue was approximately 11.7 billion yuan (-0.3%), with net profit down 14.4% [7]. - **Retail Pharmacies**: Revenue was 57.8 billion yuan (+0.1%), with net profit up 0.9% [9]. - **Pharmaceutical Distribution**: Revenue increased by 0.9% to 404.57 billion yuan, with net profit rising 12.4% [9]. - **Traditional Chinese Medicine**: Revenue decreased by 4.8% to 173 billion yuan, with net profit slightly up by 0.6% [9]. - **Vaccine Sector**: Revenue plummeted by 58.0% to 10.5 billion yuan, with a net loss of 0.5 billion yuan [11]. Financial Metrics - The overall gross margin for the industry was 32.4%, with a decline in the four expense ratios [46][49]. - The report highlights that the CXO sector showed the highest growth in both revenue and net profit, indicating a strong recovery trajectory [34][37].

Core Viewpoint - The CXO sector is experiencing stable revenue growth and significant profit increases, driven by industry recovery, improved operational efficiency, and cost reduction efforts [1][2]. Revenue and Profit Performance - In the first half of 2025, the CXO sector achieved revenue of 47.096 billion yuan, a year-on-year increase of 13.25%, and a net profit attributable to shareholders of 11.743 billion yuan, up 61.19% year-on-year [1][2]. - In Q2 2025, the CXO sector reported revenue of 24.750 billion yuan, a 13.95% increase year-on-year, and a net profit of 6.674 billion yuan, reflecting a 52.26% year-on-year growth [2]. Productivity and Efficiency - In H1 2025, per capita revenue increased to 411,100 yuan, a 12.62% year-on-year rise, while per capita profit reached 114,000 yuan, up 52.41% year-on-year, indicating improved operational efficiency [3]. - The fixed asset turnover rate was 1.00 times, a 7.03% increase year-on-year, attributed to industry recovery and enhanced operational efficiency [3]. Demand and Supply Dynamics - As of H1 2025, contract liabilities and advance receipts amounted to 7.549 billion yuan, a 3.71% year-on-year increase, indicating stabilization in industry demand and a slight recovery in orders [4]. - Fixed assets totaled 47.274 billion yuan, a 5.81% year-on-year increase, with ongoing projects valued at 15.810 billion yuan, up 7.69% year-on-year [4]. Investment Recommendations - The easing of liquidity due to anticipated interest rate cuts by the Federal Reserve is expected to positively impact market conditions [5]. - The domestic A+H share innovative drug companies are seeing significant market capitalization increases, which may enhance local investment and financing conditions [5]. - Key areas to focus on include the impact of U.S. monetary policy, changes in investment and financing dynamics, and the gradual recovery of overseas demand [5]. Company-Specific Focus - Companies benefiting from domestic innovative drug support policies include clinical CROs like Sunshine Nuohuo and Nuo Si Ge [6]. - Life sciences upstream companies with strong overseas business performance include Haoyuan Pharmaceutical and Bid Pharma [6]. - Companies involved in weight loss drugs, Alzheimer's treatments, ADC, and AI concepts, such as Hongbo Pharmaceutical, are also of interest [6]. - Companies with unexpectedly high new order signings, like Pruis, should be monitored [6].

Core Insights - The biopharmaceutical industry is experiencing an upward trend, with companies showcasing their R&D progress and global market strategies during the recent performance briefing [1] - Companies are optimistic about their development in the second half of the year, driven by high R&D investments and technological advancements [1][4] R&D Progress - Companies like Sailun Biopharma and Haohai Biological are making steady progress in product development and market expansion [1] - Sailun Biopharma plans to introduce new projects, including broad-spectrum anti-snake venom antibodies and recombinant snake venom coagulants by mid-2025 [1][2] - Haohai Biological has several innovative products in the pipeline, including a pain-free cross-linked hyaluronic acid gel for aesthetic medicine, which has entered the registration phase [2] Market Trends - The demand for algal oil DHA products is increasing, driven by the replacement of old national standards for infant formula and rising maternal and infant consumption [2][3] - Jia Bi You's sales of algal oil DHA are growing significantly, with a faster transition from fish oil DHA among major clients [3] Industry Outlook - Companies express confidence in the industry's performance in the second half of the year, with expectations of continued growth in the GLP-1 drug market due to its effectiveness in diabetes and weight loss [4] - Nawei Technology anticipates significant market expansion for GLP-1 and other peptide drugs, projecting a revenue increase of approximately 108% in the first half of 2025 [4] Innovation and Global Expansion - The demand for drug molecular building blocks is recovering, with companies like Bid Pharma expanding their compound libraries to cover mainstream targets [5] - Companies are leveraging AI in synthetic biology to enhance R&D efficiency and reduce costs [5] - Xuan Tai Pharmaceutical is pursuing a diversified market strategy, collaborating with Kalbe Farma in Indonesia to penetrate Southeast Asian markets [6]